Two companies, Vertex Pharmaceuticals and CRISPR Therapeutics, have jointly launched the first human CRISPR-Cas9 therapy for the inherited blood disorder β-thalassemia. The therapy, known as CTX001, works by cleaving a gene called BCL11A that...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)